British Journal of Clinical Pharmacology · 1988 · 33 citations · 4 references
PharmacyPharmacokineticsPharmacologyDialysisHemodialysisRenal PharmacokineticsDialysis PharmacotherapyPharmacokinetics In Renal ImpairmentRenal DiseaseRenal Drug ClearanceRenal Drug DistributionRenal PharmacologyChronic Renal InsufficiencyDrug Dosing During HemodialysisHemodialysis PharmacokineticsPharmacokinetics In DialysisPharmacokinetics In Kidney DiseaseRenal Failure ManagementRenal Impairment ClearanceRenal Plasma Clearance
1. Lisinopril and enalapril were administered as 2.5 mg single doses and as eight single daily 2.5 mg doses to separate groups of six patients with chronic renal failure. Patients were receiving regular haemodialysis. 2. In the absence of haemodialysis, the decline in plasma concentrations of lisinopril and enalaprilat was extremely slow and plasma concentrations were generally high. 3. Haemodialysis had large effects on plasma concentrations of lisinopril and enalaprilat. A 4 h period reduced plasma concentrations of both drugs by around one-half and often by significantly more than this. Even 1 or 2 h of haemodialysis had significant effects. 4. Haemodialysis plasma clearance was similar for both drugs with mean values of the order of 40 ml min-1. Clearance did not markedly differ when measured after 1, 2 or 4 h of haemodialysis or after single or multiple doses of lisinopril or enalapril. 5. The design of dosage regimens of both lisinopril and enalapril for patients with severe renal impairment or chronic renal failure should take into consideration the use and effects of haemodialysis.
4
Enalapril maleate and a lysine analogue (MK‐521): disposition in man.
E H Ulm, M Hichens, HJ Gomez et al. · British Journal of Clinical Pharmacology · 1982 · 214 citations · Full text
The effect of renal function on enalapril kinetics
David Löwenthal, John D. Irvin, Donna Merrill et al. · Clinical Pharmacology & Therapeutics · 1985 · 41 citations